Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10085138 | 0.88 | HDAC3 (0.30) | — | |
| SCHEMBL10085147 | 0.83 | MC5R (0.42) | ACHE | |
| SCHEMBL13596207 | 0.77 | TSHR (0.31) | — | |
| SCHEMBL16315919 | 0.76 | CHRM2 (0.40) | ACHE | |
| SCHEMBL16016666 | 0.75 | CHRM2 (0.34) | — | |
| SCHEMBL13045430 | 0.74 | ACHE (0.36) | ACHE | |
| SCHEMBL12387578 | 0.74 | ACHE (0.36) | ACHE | |
| SCHEMBL14524602 | 0.74 | ACHE (0.36) | ACHE | |
| SCHEMBL10085181 | 0.74 | ACHE (0.36) | ACHE | |
| SCHEMBL13992424 | 0.74 | CHRM2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027677-A1 | Prion-specific peptoid reagents | NOVARTIS AG | 2012-02-02 | — | — | US | disclosed |
| US-20120027677-A1 | Prion-specific peptoid reagents | NOVARTIS AG | 2012-02-02 | — | — | US | disclosed |
| US-20110189692-A1 | ASSAY FOR PATHOGENIC CONFORMERS | NOVARTIS AG | 2011-08-04 | — | — | US | disclosed |
| US-20110189692-A1 | ASSAY FOR PATHOGENIC CONFORMERS | NOVARTIS AG | 2011-08-04 | — | — | US | disclosed |
| US-7834144-B2 | Prion-specific peptoid reagents | NOVARTIS AG (CH) | 2010-11-16 | — | — | US | disclosed |
| US-7834144-B2 | Prion-specific peptoid reagents | NOVARTIS AG (CH) | 2010-11-16 | — | — | US | disclosed |
| US-20070087972-A1 | Prion-specific peptoid reagents | NOVARTIS AG (CH) | 2007-04-19 | — | — | US | disclosed |
| US-20070087972-A1 | Prion-specific peptoid reagents | NOVARTIS AG (CH) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087972-A1 | Prion-specific peptoid reagents | PRNP, PARL, PCNP | ACHE 4283/4885 |
| US-20120027677-A1 | Prion-specific peptoid reagents | PRNP, PARL, PCNP | ACHE 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.